Arrowhead Pharmaceuticals Inc’s recently made public that its Chief Discovery/Trans Medicine Hamilton James C unloaded Company’s shares for reported $0.65 million on Jan 06 ’25. In the deal valued at $19.82 per share,32,729 shares were sold. As a result of this transaction, Hamilton James C now holds 272,122 shares worth roughly $5.03 million.
Then, O’Brien Patrick sold 29,184 shares, generating $578,539 in total proceeds. Upon selling the shares at $19.82, the COO and General Counsel now owns 535,201 shares.
Before that, O’Brien Patrick sold 8,000 shares. Arrowhead Pharmaceuticals Inc shares valued at $157,520 were divested by the COO and General Counsel at a price of $19.69 per share. As a result of the transaction, O’Brien Patrick now holds 527,201 shares, worth roughly $9.75 million.
Goldman initiated its Arrowhead Pharmaceuticals Inc [ARWR] rating to a Neutral in a research note published on June 05, 2024; the price target was $31. A number of analysts have revised their coverage, including BofA Securities’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Citigroup began covering ARWR with “Neutral” recommendation on September 19, 2023. TD Cowen started covering the stock on July 21, 2023. It rated ARWR as “an Outperform”.
Price Performance Review of ARWR
On Friday, Arrowhead Pharmaceuticals Inc [NASDAQ:ARWR] saw its stock fall -6.38% to $18.49. Over the last five days, the stock has lost -5.90%. Arrowhead Pharmaceuticals Inc shares have fallen nearly -1.65% since the year began. Nevertheless, the stocks have fallen -51.43% over the past one year. While a 52-week high of $39.83 was reached on 01/08/25, a 52-week low of $17.05 was recorded on 01/10/25. SMA at 50 days reached $20.91, while 200 days put it at $23.15.
Levels Of Support And Resistance For ARWR Stock
The 24-hour chart illustrates a support level at 17.92, which if violated will result in even more drops to 17.36. On the upside, there is a resistance level at 19.23. A further resistance level may holdings at 19.98. The Relative Strength Index (RSI) on the 14-day chart is 37.69, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.06, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.45%. Stochastics %K at 29.66% indicates the stock is a holding.
How much short interest is there in Arrowhead Pharmaceuticals Inc?
A steep rise in short interest was recorded in Arrowhead Pharmaceuticals Inc stocks on 2024-11-15, growing by 0.11 million shares to a total of 9.45 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 9.33 million shares. There was a rise of 1.17%, which implies that there is a positive sentiment for the stock.
